{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:50:16Z","timestamp":1792122616291,"version":"4.4.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Endometrial carcinoma (EC) is classified into four distinct molecular subgroups. Patients with polymerase epsilon exonuclease domain mutated (POLE-EDM) tumors have the best prognosis of all. This meta-analysis consolidated the clinicopathology variations reported in the POLE-mutant subtype and survival parameters in patients with EC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The following internet data bases were searched: PubMed, Web of science, Embase and Scimage directory. Data was extracted from eligible studies including sample size, number of positive POLE-mutant cases, EDM sequencing information, clinicopathologic, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odds ratios (OR).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The meta-analysis included 11 cohort studies comprising 5508 EC patients (442 POLE EDM tumors). Patients with POLE mutant EC were associated with improved disease specific survival (HR = 0.408, 95% CI: 0.306 to 0.543) and progression-free survival (HR = 0.231, 95% CI: 0.117 to 0.456). POLE-mutated tumors were mostly endometrioid histology (84.480%; 95% CI: 77.237 to 90.548), although not significantly more than wild type tumors (OR = 1.386; p = 0.073). The POLE mutant tumors significantly present (p&lt;0.001) at Federation of International of Gynecologists and Obstetricians (FIGO) lower stages I-II (OR = 2.955, p&lt;0.001) and highest grade III (OR = 1.717, P = 0.003). The tumors are significantly associated with invasion less than half (&lt;50%) of the myometrium (OR = 1.765, p = 0.001), but not deeply invasive EC (MI&gt;50%, OR = 0.83, p = 0.34). POLE mutations significantly protected against lymph node metastases (OR = 0.202, p = 0.001), and have no clear association with lymph-vascular space invasion (OR = 0.967, 95% 0.713\u20131.310, p = 0.826). The tumors are predominantly of low ESMO risk stratification distribution (40.356%; 95% CI: 27.577 to 53.838).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>POLE mutations serve as an important biomarker of favorable prognosis in EC. The tumors are characteristically high grade, early stage, and remain localized in the endometrium with reduced likelihood of lymph node metastasis for improved survival prospects and the lowest risk classification. These findings have implications for medical management of EC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0263585","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T18:36:44Z","timestamp":1644431804000},"page":"e0263585","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Alaa Salah","family":"Jumaah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawraa Sahib","family":"Al-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2893-7706","authenticated-orcid":true,"given":"Katherine Ann","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeel Abed","family":"Yasseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"1","key":"pone.0263585.ref001","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13104-019-4756-4","article-title":"Increased PTEN gene expression in patients with endometrial carcinoma from areas of high risk depleted uranium exposure.","volume":"12","author":"AS Jumaah","year":"2019","journal-title":"BMC Res Notes"},{"issue":"1","key":"pone.0263585.ref002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017.","volume":"67","author":"RL Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0263585.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.","volume":"27","author":"N Colombo","year":"2016","journal-title":"Ann Oncol."},{"issue":"9","key":"pone.0263585.ref004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14737140.2018.1491311","article-title":"Management Strategies for Recurrent Endometrial Cancer.","volume":"18","author":"EV Connor","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"pone.0263585.ref005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International Patterns and Trends in Endometrial Cancer Incidence, 1978\u20132013","volume":"110","author":"J Lortet-Tieulent","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"pone.0263585.ref006","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.","volume":"37","author":"CB Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"pone.0263585.ref007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ejca.2012.09.006","article-title":"A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis","volume":"49","author":"HM Werner","year":"2013","journal-title":"Eur J Cancer"},{"issue":"16","key":"pone.0263585.ref008","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts","volume":"22","author":"E Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7447","key":"pone.0263585.ref009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"issue":"5","key":"pone.0263585.ref010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.","volume":"29","author":"S Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"pone.0263585.ref011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"A Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"pone.0263585.ref012","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"A Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"pone.0263585.ref013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061478","article-title":"The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions.","volume":"13","author":"M Alexa","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0263585.ref014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/path.4185","article-title":"Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers","volume":"230","author":"S Briggs","year":"2013","journal-title":"J Pathol"},{"issue":"1","key":"pone.0263585.ref015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2014.05.006","article-title":"POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium","volume":"134","author":"B Meng","year":"2014","journal-title":"Gynecol Oncol"},{"key":"pone.0263585.ref016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gde.2013.12.005","article-title":"Replicative DNA polymerase mutations in cancer","volume":"24","author":"E Heitzer","year":"2014","journal-title":"Curr Opin Genet Dev"},{"issue":"25","key":"pone.0263585.ref017","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"34","author":"DS McMeekin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0263585.ref018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"E Stelloo","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"pone.0263585.ref019","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/his.13338","article-title":"Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf\u2019s clothing.","volume":"72","author":"IC Van Gool","year":"2018","journal-title":"Histopathology"},{"issue":"6","key":"pone.0263585.ref020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4132\/jptm.2020.07.23","article-title":"The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis","volume":"54","author":"AS Jumaah","year":"2020","journal-title":"J Pathol Transl Med"},{"issue":"8","key":"pone.0263585.ref021","doi-asserted-by":"crossref","first-page":"e19281","DOI":"10.1097\/MD.0000000000019281","article-title":"Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis","volume":"99","author":"Y He","year":"2020","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"pone.0263585.ref022","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cncr.29046","article-title":"Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.","volume":"121","author":"CC Billingsley","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"pone.0263585.ref023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.","volume":"42","author":"T Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"pone.0263585.ref024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"DN Church","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"pone.0263585.ref025","doi-asserted-by":"crossref","first-page":"e0214318","DOI":"10.1371\/journal.pone.0214318","article-title":"Phenotype of POLE-mutated endometrial cancer.","volume":"14","author":"S Imboden","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"pone.0263585.ref026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"AN Karnezis","year":"2017","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"pone.0263585.ref027","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2017.06.020","article-title":"Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer","volume":"146","author":"L Proctor","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"8","key":"pone.0263585.ref028","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma","volume":"25","author":"A Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0263585.ref029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"N Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"pone.0263585.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"D Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"Suppl 6","key":"pone.0263585.ref031","doi-asserted-by":"crossref","first-page":"vi33","DOI":"10.1093\/annonc\/mdt353","article-title":"Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"24","author":"N Colombo","year":"2013","journal-title":"Ann Oncol."},{"issue":"7414","key":"pone.0263585.ref032","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"pone.0263585.ref033","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JA Sterne","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"pone.0263585.ref034","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"PF Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0263585.ref035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12881-019-0936-2","article-title":"POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF\/AMFR signal transduction","volume":"20","author":"Y Li","year":"2019","journal-title":"BMC Med Genet"},{"issue":"14","key":"pone.0263585.ref036","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer","volume":"21","author":"IC van Gool","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0263585.ref037","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2016.11.023","article-title":"Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.","volume":"144","author":"S Bellone","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"pone.0263585.ref038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbcan.2019.06.002","article-title":"Metastasis as a systemic disease: molecular insights and clinical implications","volume":"1872","author":"M Aleckovic","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"pone.0263585.ref039","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pathol.2017.09.010","article-title":"Molecular insights into the classification of high-grade endometrial carcinoma.","volume":"50","author":"YR Hussein","year":"2018","journal-title":"Pathology"},{"issue":"6","key":"pone.0263585.ref040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/his.12878","article-title":"Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.","volume":"68","author":"S Bakhsh","year":"2016","journal-title":"Histopathology"},{"issue":"Suppl 2","key":"pone.0263585.ref041","doi-asserted-by":"crossref","first-page":"ii19","DOI":"10.1093\/annonc\/mdn113","article-title":"Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.","volume":"19","author":"MM Baekelandt","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"pone.0263585.ref042","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"A Leon-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"4","key":"pone.0263585.ref043","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/modpathol.2014.143","article-title":"Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.","volume":"28","author":"YR Hussein","year":"2015","journal-title":"Mod Pathol"},{"issue":"1","key":"pone.0263585.ref044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2015.12.031","article-title":"Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas","volume":"141","author":"A Wong","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"12","key":"pone.0263585.ref045","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.","volume":"30","author":"A van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0263585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T18:37:25Z","timestamp":1644431845000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0263585"}},"subtitle":[],"editor":[{"given":"Manish S.","family":"Patankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0263585","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]}}}